Concord Biotech Ltd Faces Mildly Bearish Momentum Amid Technical Shifts

Technical Trend Overview

Concord Biotech’s technical trend has shifted from a sideways pattern to a mildly bearish stance, reflecting growing caution among traders. The daily moving averages have turned mildly bearish, indicating that short-term price action is losing upward momentum. The stock closed at ₹1,332.70 on 21 Jul 2026, down 0.52% from the previous close of ₹1,339.60, with intraday prices ranging between ₹1,330.00 and ₹1,357.20.

The 52-week price range remains wide, with a high of ₹1,979.20 and a low of ₹987.05, underscoring significant volatility over the past year. This volatility is a key consideration for investors assessing risk and reward in the current market environment.

MACD and Momentum Signals

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On the weekly chart, MACD remains bullish, suggesting that medium-term momentum retains some strength. However, the monthly MACD has turned mildly bearish, signalling that longer-term momentum is weakening. This divergence between weekly and monthly MACD readings highlights a transitional phase where short- to medium-term optimism is tempered by longer-term caution.

RSI and Overbought/Oversold Conditions

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This absence of extreme overbought or oversold conditions suggests that the stock is not presently stretched in either direction, leaving room for further price discovery but also indicating a lack of strong directional conviction among traders.

Bollinger Bands and Price Volatility

Bollinger Bands provide additional insight into price volatility and trend strength. On the weekly scale, the bands are mildly bullish, implying that price movements are slightly favouring upward momentum within a contained volatility range. Conversely, the monthly Bollinger Bands are mildly bearish, reinforcing the longer-term caution signalled by the monthly MACD. This mixed signal environment suggests that while short-term price action may see modest gains, the broader trend remains under pressure.

Moving Averages and KST Indicator

Daily moving averages have turned mildly bearish, signalling that recent price action is losing upward momentum. This is consistent with the weekly KST (Know Sure Thing) indicator, which is bearish, reinforcing the short- to medium-term downtrend. The monthly KST reading is not available, but the existing data suggests caution for investors relying on momentum-based strategies.

Volume and Dow Theory Signals

On-Balance Volume (OBV) indicators for both weekly and monthly periods show no discernible trend, indicating that volume is not confirming either bullish or bearish price action. Similarly, Dow Theory analysis reveals no clear trend on weekly or monthly charts, reflecting a lack of consensus among market participants about the stock’s directional bias.

Comparative Performance Against Sensex

Concord Biotech’s recent returns have lagged behind the benchmark Sensex index. Over the past week, the stock declined by 1.46%, while Sensex gained 0.12%. Over the last month, Concord Biotech posted a modest 1.23% gain, slightly outperforming Sensex’s 1.18%. Year-to-date, the stock is down 0.95%, whereas Sensex has declined by 8.81%, indicating relative resilience in a broader market downturn.

However, over the last year, Concord Biotech has underperformed significantly, with a 29.63% loss compared to Sensex’s 4.95% decline. This underperformance over the 12-month horizon highlights challenges the company faces amid sectoral and market headwinds.

MarketsMOJO Rating and Outlook

MarketsMOJO has downgraded Concord Biotech from Hold to Sell as of 15 Jun 2026, reflecting deteriorating technical and fundamental outlooks. The Mojo Score stands at 42.0, categorising the stock as a Sell. The small-cap status adds to the risk profile, as liquidity and volatility concerns remain pertinent for investors.

The downgrade is consistent with the mildly bearish technical signals and the stock’s recent price momentum. Investors should weigh these factors carefully, especially given the mixed signals from technical indicators and the stock’s relative underperformance over the past year.

Investment Implications and Strategy

Given the current mildly bearish technical environment and the downgrade by MarketsMOJO, investors should approach Concord Biotech with caution. The mixed signals from MACD, Bollinger Bands, and moving averages suggest that while short-term rallies are possible, the broader trend is under pressure.

Investors with a higher risk tolerance might consider monitoring the weekly MACD bullishness for potential entry points, but the monthly bearish indicators counsel prudence. The neutral RSI readings imply that the stock is not yet oversold, so further downside cannot be ruled out.

Comparing Concord Biotech’s performance with the Sensex reveals that the stock has struggled over the last year, which may reflect sector-specific challenges or company-specific issues. This underperformance, combined with the small-cap risk, suggests that investors might benefit from diversifying into more stable or outperforming stocks within the Pharmaceuticals & Biotechnology sector or other sectors altogether.

Conclusion

Concord Biotech Ltd is currently navigating a complex technical landscape marked by a shift to mildly bearish momentum and a downgrade in analyst sentiment. While some weekly indicators retain bullish elements, the monthly signals and moving averages point to caution. The stock’s recent price action and relative underperformance against the Sensex reinforce the need for a measured investment approach.

Investors should closely monitor technical developments, particularly the MACD and moving averages, alongside fundamental updates, to gauge whether the stock can regain upward momentum or if further downside is likely. In the meantime, exploring alternative investment opportunities within the sector or broader market may offer better risk-adjusted returns.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →